Skip to main navigation Skip to search Skip to main content

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry

  • Amira Souissi
  • , Francesco Patti
  • , Tim Spelman
  • , Clara Chisari
  • , Amina Gargouri
  • , Nevin John
  • , Allan G. Kermode
  • , Tomas Kalincik
  • , Helmut Butzkueven
  • , Seyed Aidin Sajedi
  • , Jeannette Lechner-Scott
  • , Izanne Roos
  • , Guy Laureys
  • , Bruce Taylor
  • , Raed Alroughani
  • , Samia J. Khoury
  • , Richard Macdonell
  • , Bianca Weinstock-Guttman
  • , Eva Kubala Havrdova
  • , Davide Maimone
  • Stephen Reddel, Marzena Fabis-Pedrini, Barbara Willekens, Abdorreza Naser Moghadasi, Patrice Lalive, Alessandra Lugaresi, Serkan Ozakbas, Claudio Solaro, Simón Cárdenas-Robledo, Vahid Shaygannejad, Masoud Etemadifar, Cavit Boz, Sara Eichau, Valentina Tomassini, Murat Terzi, Alexandre Prat, Mario Habek, Yolanda Blanco, Ayse Altintas, Oliver Gerlach, Recai Turkoglu, Katherine Buzzard, Olga Skibina, Aysun Soysal, Anneke van der Walt, Stella Hughes, Vincent van Pesch, Matteo Foschi, Andrea Surcinelli, Julie Prevost, Cristina Ramo-Tello, Chris McGuigan, Maria Jose Sa, Jens Kuhle, Daniele Spitaleri, Bhim Singhal, Radek Ampapa, Koen de Gans, Thor Petersen, Mihaela Simu, Emmanuelle Lapointe, Jose Luis Sanchez-Menoyo, Orla Gray, Justin Garber, Eduardo Aguera-Morales, Katrin Gross-Paju, Tamara Castillo-Triviño, Abdullah Al-Asmi, Nikolaos Grigoriadis, Jihad Inshasi, Talal Al-Harbi, Todd A. Hardy, Sudarshini Ramanathan, Melissa Cambron, Neil Shuey, Angel Perez sempere, Tunde Csepany, Irene Treviño-Frenk, Csilla Rozsa, Marija Cauchi, Rana Karabudak, Saloua Mrabet, Riadh Gouider
  • Razi University Hospital
  • Université de Tunis El Manar
  • University of Catania
  • Karolinska Institutet
  • MSBase Foundation
  • School of Clinical Sciences at Monash Health
  • University of Western Australia
  • Murdoch University
  • Royal Melbourne Hospital
  • University of Melbourne
  • Alfred Health
  • Monash University
  • Golestan University of Medical Sciences
  • University of Newcastle
  • Hunter New England Health
  • Ghent University
  • Royal Hobart Hospital
  • University of Tasmania
  • Department of Medicine—Amiri Hospital
  • American University of Beirut
  • Austin Health
  • Charles University
  • Centro Sclerosi Multipla
  • Concord Repatriation General Hospital
  • University of Antwerp
  • Tehran University of Medical Sciences
  • University of Geneva
  • University of Bologna
  • Izmir Ekonomi University
  • Galliera Hospital
  • Universidad Nacional de Colombia
  • Isfahan University of Medical Sciences
  • Karadeniz Technical University
  • Hospital Universitario Virgen Macarena
  • Gabriele d'Annunzio University
  • Annunziata University Hospital
  • Ondokuz Mayis University
  • University of Montreal
  • University of Zagreb
  • Hospital Clinic de Barcelona
  • Koc University
  • Zuyderland
  • Maastricht University
  • Ministry of Health, Turkey
  • Box Hill Hospital
  • Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases
  • Royal Victoria Hospital Belfast
  • Université catholique de Louvain
  • Ospedale S. Maria delle Croci
  • University of L'Aquila
  • CSSS Saint-Jérôme
  • Generalitat de Catalunya
  • University College Dublin
  • Centro Hospitalar Universitário de São João
  • University Fernando Pessoa
  • University of Basel
  • Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino
  • Bombay Hospital and Medical Research Centre
  • Nemocnice Jihlava
  • Groene Hart Ziekenhuis
  • Aarhus University
  • Victor Babes University of Medicine and Pharmacy
  • Centre Hospitalier Universitaire de Sherbrooke
  • Galdakao-Usansolo University Hospital
  • Biocruces-Bizkaia Health Research Institute
  • South Eastern Health and Social Care Trust
  • Westmead Hospital
  • University of Córdoba
  • Maimonides Biomedical Research Institute of Cordoba (IMIBIC)
  • Multiple Sclerosis Centre
  • Hospital Universitario Donostia
  • Sultan Qaboos University
  • AHEPA University Hospital
  • Aristotle University of Thessaloniki
  • Dubai Hospital
  • King Fahad Specialist Hospital, Dammam
  • The University of Sydney
  • AZ Sint-Jan Brugge
  • Vincents Hospital
  • Hospital General Universitario de Alicante
  • Miguel Hernández University
  • University of Debrecen
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  • Jahn Ferenc Teaching Hospital
  • Mater Dei Hospital
  • Yeditepe University

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Multiple Sclerosis (MS) severity is influenced by several factors. Understanding the impact of age at disease onset may help to better characterize clinical and disease features across age groups. This study aimed to characterize the clinical features and disability outcomes of late-onset MS (LOMS) and very late-onset MS (vLOMS), compared to adult-onset MS (AOMS). Methods: We conducted an observational study using data from the MSBase registry and categorized patients based on age at MS onset: AOMS (18–39 years), transition onset (40–49 years), LOMS (50–59 years), and vLOMS (≥ 60 years). Disease progression was assessed using the 24 week confirmed disability progression, EDSS4 and 6 milestones, conversion to secondary progressive MS(SPMS), and the first progression independent of relapse activity (PIRA) event. Cox proportional hazard regression models were used to determine unadjusted hazard ratios(HR), and propensity score inverse probability of treatment weighting(PS-IPTW) balanced covariate distributions. Results: Among 81,236 patients, 5.2% had LOMS and 1% had vLOMS. Primary progressive MS was more frequent in LOMS and vLOMS (21.7 and 24%, respectively). Patients with LOMS and vLOMS had a significantly increased risk of 24 week confirmed disability progression (HR:LOMS = 1.39, vLOMS = 1.80), EDSS 4 (HR:LOMS = 2.14, vLOMS = 2.95), EDSS 6 (HR:LOMS = 2.33, vLOMS = 6.33), SPMS (HR:LOMS = 1.62, vLOMS = 2.38), and first PIRA event (HR:LOMS = 2.12, vLOMS = 2.93). Conclusion: LOMS and vLOMS exhibited a more progressive disease onset and higher disability milestones compared with AOMS.

Original languageEnglish
Article number114
JournalJournal of Neurology
Volume273
Issue number2
DOIs
StatePublished - Feb 2026

Keywords

  • Aging
  • Immunosenescence
  • Multiple Sclerosis
  • Prognosis
  • Progression

Fingerprint

Dive into the research topics of 'Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry'. Together they form a unique fingerprint.

Cite this